Browse the evidence

Tirzepatide (5-15 mg weekly) does not increase the risk of adjudication-confirmed pancreatitis compared to placebo, insulin, or GLP-1 receptor agonists, despite causing greater elevations in serum pancreatic amylase and lipase.

If you are prescribed Tirzepatide for weight loss or diabetes, do not panic if your blood tests show higher pancreatic enzymes. The data shows this is a common side effect of the drug's mechanism but does not translate to actual pancreatitis. Routine monitoring is still advised, but the risk of clinical pancreatitis is no higher than with other standard treatments.

Switching antipsychotics to Aripiprazole results in significant weight reduction, but adding Aripiprazole to an existing regimen is not recommended due to increased risks of agitation and akathisia.

If you are gaining weight on your current antipsychotic, switching to Aripiprazole can lead to significant weight loss. However, do not simply add Aripiprazole to your current medication, as this can cause agitation and anxiety. Switching must be done carefully with your doctor, weighing the mental health stability against the metabolic benefits.

Initiating insulin glargine in patients with type 2 diabetes is associated with a higher risk of gastroparesis, intestinal obstruction, and all-cause mortality compared to initiating SGLT2 inhibitors.

If you are considering insulin glargine for type 2 diabetes, know that it is associated with a higher risk of gastroparesis, intestinal obstruction, and death compared to SGLT2 inhibitors. This does not mean insulin is bad, but it highlights the importance of choosing the right medication for your specific health profile. If you are at risk for GI issues, SGLT2 inhibitors might be a safer choice.

Knockout of the microprotein encoded by Adipocyte-smORF-1183 significantly impairs adipocyte differentiation and reduces lipid droplet formation.

This research identifies a specific, previously unknown protein (Adipocyte-smORF-1183) in mouse fat cells that is essential for storing fat. Knocking out this protein reduces fat storage by about half in these cells. While this is a fundamental biological discovery that could lead to future therapies for obesity, it is currently limited to cell culture models and does not yet translate to a direct human treatment or lifestyle intervention.

Higher circulating estrogen levels in women are predictive of increased rates of nausea and vomiting when taking GLP-1 receptor agonists, and estrous cycle phase modulates drug sensitivity in female mice.

Your risk of side effects from GLP-1 drugs may fluctuate with your menstrual cycle, peaking when estrogen is highest. While this paper used mice, human data suggests higher estrogen levels correlate with more nausea. Tracking your cycle might help you and your doctor anticipate and manage side effects.

Low baseline ribosome-related gene expression and resistance training-induced declines in ribosome-related gene expression are associated with greater skeletal muscle hypertrophy in young men and women.

If you are struggling to build muscle despite consistent resistance training, your baseline cellular machinery (ribosomes) might be a limiting factor, but this is largely genetic or determined by prior activity levels. The key takeaway is that 'more' isn't always 'better' for muscle growth; your body may adapt by becoming more efficient with what it has rather than expanding its capacity. Focus on progressive overload and consistency, as the body's response is individual and not strictly dictated by having the highest possible baseline ribosome levels.

GLP-1RA treatment induces distinct molecular changes in skeletal muscle proteome (upregulation of mitochondrial proteins) compared to calorie restriction, despite similar weight loss and muscle mass changes.

This finding is primarily mechanistic and suggests GLP-1s may improve muscle metabolic efficiency (mitochondrial function) beyond just weight loss, though this does not currently translate to a specific user action beyond standard treatment.

GLP-1 receptor agonists and MC4R modulators are emerging therapeutic strategies that target hypothalamic pathways to treat metabolic diseases.

Current treatments for obesity and diabetes, such as GLP-1 receptor agonists, work by targeting specific pathways in the hypothalamus. This highlights the importance of central nervous system mechanisms in these conditions and supports the use of these medications as effective treatments.

GLP-1 receptor agonists slow renal disease progression and reduce albuminuria in patients with diabetic kidney disease, although evidence is less robust than for SGLT2 inhibitors.

If you have diabetic kidney disease, GLP-1 receptor agonists may help slow kidney damage and reduce protein in your urine. While there is less data on their kidney benefits compared to SGLT2 inhibitors, they are still considered valuable. Discuss with your doctor if they are appropriate for you, especially if you have cardiovascular risks.

Orforglipron is associated with a dose-dependent increase in gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) and treatment discontinuation rates, particularly at doses of 12 mg and higher.

While effective, orforglipron often causes stomach problems like nausea, vomiting, and diarrhea, especially at higher doses (12 mg and above). These side effects are the main reason people stop taking the medication. Patients should be aware that higher doses provide more weight loss but also carry a higher risk of stopping treatment due to discomfort. Starting at a lower dose and titrating slowly may help manage these side effects.

Discontinuing or interrupting GLP-1 receptor agonist (GLP-1RA) treatment progressively erodes cardiovascular protection, with longer durations of non-use associated with a graded increase in the risk of major adverse cardiovascular events (MACE).

If you have Type 2 Diabetes and take a GLP-1RA (like Ozempic or Wegovy), your heart protection is tied to continuous use. Stopping the medication does not leave you in a 'safe' state; it actively increases your risk of heart attack or stroke, and the longer you stay off the drug, the higher that risk becomes. If you must stop due to side effects or cost, do not just stop abruptly; consult your provider for a strategy to manage the increased cardiovascular risk during the transition.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) do not increase the risk of thyroid or pancreatic cancer in humans, despite animal model concerns.

If you are prescribed a GLP-1 agonist like semaglutide or liraglutide, you do not need to worry about an increased risk of thyroid or pancreatic cancer based on current human data. The FDA warning is based on animal studies, and large human trials have not confirmed this risk.

Bariatric surgery reduces the overall incidence and mortality of cancer, with a more pronounced effect in women than men.

Bariatric surgery is a highly effective intervention for reducing the risk of cancer and cancer-related mortality in people with obesity. The benefit is particularly strong for women, likely due to the reduction in hormone-dependent cancers. The risk reduction is directly linked to the amount of weight lost.

Pharmacological inhibition or genetic deletion of the melanocortin-3 receptor (MC3R) enhances the anorectic and weight-loss efficacy of GLP-1 receptor agonists (e.g., liraglutide, semaglutide, tirzepatide) without increasing malaise or peripheral incretin effects.

Current research indicates that blocking the MC3R receptor can make GLP-1 weight loss drugs (like Ozempic or Wegovy) work better, allowing for lower doses to achieve the same weight loss. This happens without increasing the nausea or stomach upset often associated with these drugs. However, effective MC3R-blocking drugs that can cross into the brain are not yet widely available for human use.

MC3R inhibition generalizes to enhance sensitivity to other anorectic hormones, including leptin, peptide YY (PYY3-36), and cholecystokinin (CCK).

Blocking the MC3R receptor doesn't just help GLP-1 drugs; it may also make your body's natural satiety signals (like leptin and gut hormones) work more effectively. This suggests a broader benefit for appetite control beyond just one drug class.

High-sensitivity ELISA assays are required to detect exercise-induced reductions in fasting insulin, whereas standard automated immunoassays (e.g., Immulite 2000) fail to capture these changes despite high correlation with international standards.

If you are tracking insulin response to lifestyle changes (like exercise or diet), ensure your laboratory uses a high-sensitivity ELISA assay. Standard automated immunoassays may report 'normal' or unchanged insulin levels even when significant metabolic improvements have occurred, leading to a false conclusion that the intervention is ineffective.

Current clinical-metabolomic biomarkers (including BCAA and lipid profiles) cannot predict individual changes in insulin sensitivity following lifestyle interventions, despite their ability to correlate with baseline insulin levels.

Do not rely on current commercial metabolomic tests (like BCAA or detailed lipid panels) to predict whether you will lose weight or improve insulin sensitivity through exercise. These tests may tell you your current risk status, but they cannot tell you how your body will respond to a specific lifestyle change.

SGLT2 inhibitors (specifically empagliflozin and canagliflozin) provide significant cardiovascular benefits, particularly reducing cardiovascular death and heart failure hospitalizations, primarily through hemodynamic mechanisms like intravascular volume reduction, with efficacy potentially modified by the duration of diabetes.

If you have Type 2 Diabetes and existing heart issues, ask your doctor about SGLT2 inhibitors like empagliflozin. They have been proven to significantly reduce the risk of dying from heart causes and hospitalizations for heart failure, likely by reducing fluid volume in the body. This benefit is most pronounced in patients with established cardiovascular disease.

Intensive glycemic control reduces cardiovascular mortality only in patients with early-stage diabetes (duration <10-15 years), whereas it may increase mortality in patients with long-standing diabetes.

If you have had Type 2 Diabetes for many years (over 10), aiming for very low blood sugar levels might actually increase your risk of death due to side effects like severe hypoglycemia. Focus on stable control rather than aggressive lowering. If you have recently been diagnosed, aggressive control can provide long-term 'legacy' protection for your heart.

Obesity directly causes chronic kidney disease (CKD) and end-stage renal disease (ESRD) through compensatory hyperfiltration, intraglomerular hypertension, and direct adipose tissue endocrine effects, independent of diabetes and hypertension.

High body weight, particularly visceral fat, directly stresses the kidneys through increased pressure and inflammatory signals, leading to chronic kidney disease even without diabetes. Managing weight through lifestyle changes is a primary strategy to prevent kidney damage.

The enteric nervous system (ENS) directly senses luminal nutrients (glucose, fatty acids, amino acids) via specific receptors and ion channels on enteric neurons, independent of enteroendocrine cell intermediaries.

Your gut has its own nervous system that directly senses nutrients like glucose and fats, not just through hormones but through direct neural pathways. This 'second brain' communicates with your central brain to regulate hunger and satiety. Understanding this can help explain why certain foods trigger immediate physiological responses and why gut health is crucial for metabolic regulation.

GLP-1 release is significantly blunted or absent in morbidly obese individuals and those with type 2 diabetes, contributing to dysregulated nutrient sensing and appetite control.

In obesity and type 2 diabetes, the body's natural production of GLP-1, a hormone that helps you feel full, is often blunted. This makes it physiologically harder to regulate food intake. Treatments that mimic GLP-1 (like GLP-1 agonists) work by restoring this signal, highlighting the importance of this pathway in weight management.

Bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB), restores GLP-1 secretion by rapidly delivering nutrients to the distal gut where L-cells are concentrated, leading to increased satiety and weight loss.

Bariatric surgery, like RYGB, works partly by changing how your gut hormones respond to food. By delivering nutrients to the distal gut faster, it triggers a surge in GLP-1, a hormone that promotes satiety. This hormonal reset is a key factor in the weight loss achieved after surgery.

GLP-1 receptor agonists significantly delay gastric emptying and increase residual gastric content, but do not significantly increase the absolute risk of pulmonary aspiration in standard endoscopic procedures.

If you take GLP-1s (like Ozempic or Wegovy) for an endoscopy, expect your stomach to empty slower, but know the risk of lung infection is very low. You likely do not need to stop your medication unless you have specific symptoms or high-risk procedures. Follow extended clear-liquid fasting instructions and use gastric ultrasound if available to ensure safety.